In Italia le terze dosi di vaccino somministrate viaggiano oltre le 700 mila unità e si inizia a valutare l'opportunità di estenderne l'utilizzo. Nel mezzo della discussione arriva lo studio Pfizer che sembra attestare l'elevata efficacia del "booster" anche sulla variante Delta
Gsk in rally a Londra. Lavora all'Ipo del consumer health ma i private, da Blackstone e Kkr a Cvc, sono in manovra sul business, che vale 47 miliardi.
Ecco 3 titoli azionari che offrono ottimi rendimenti, oltre a prospettive di crescita piuttosto buone.
Moderna peggiore a Wall Street. Il titolo non è più buy in scia ai positivi risultati dell'antivirale Molnupiravir di Merck & Co., che vola al Nyse.
Non si ferma la stagione dell'M&A, con le Big Pharma che guardano oltre i vaccini contro il Covid-19. E Merck acquista Acceleron per 11,5 miliardi.
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitisdi Business Wire
Il Consiglio di Amministrazione di Philogen e, insieme alla sua controllata svizzera Philochem AG, ha approvato il bilancio consolidatosemestrale abbreviatoal 30giugno2021.
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Agedi Business Wire
Formal submission to request Emergency Use Authorization to follow in the coming weeks
Influenza results in approximately 5 million cases of severe illness and 290,000 to up to 650,000 deaths worldwide every year,1 with current seasonal vaccines preventing 40% to 60% of the disease in the best-matched seasons 2
mRNA-based vaccine design requires only the genetic sequences of the viruses, enabling more flexible, rapid manufacturing and the potential opportunity to improve upon the efficacy of current flu vaccines
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adultsdi Business Wire
EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) is the third study launched in this global clinical research program.
New study will evaluate novel protease inhibitor (PF-07321332, co-administered with a low dose of ritonavir) for prevention of illness in adults living in the same household as someone with COVID-19
PF-07321332 has been specifically designed to be administered orally, so that it can potentially be administered at the first sign of infection with, or exposure to, SARS-CoV-2, without requiring patients to be hospitalized
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analystsdi Business Wire
Board of Directors approves quarterly cash dividend of $0.39 per share
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Boosterdi Business Wire
Emergency Use Authorization (EUA) granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
EUA is supported by clinical data showing a booster dose of the Pfizer-BioNTech vaccine elicits high neutralization titers against SARS-CoV-2 and all currently tested variants
Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series
A booster dose given at least six months after completion of the primary vaccination series may help preserve a high level of protection against COVID-19
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countriesdi Business Wire
Expanded agreement brings the total number of COVID-19 vaccine doses to be supplied to the U.S. government for donation to one billion
Effort contributes to companies’ pledge to deliver two billion COVID-19 vaccine doses to low- and middle-income countries by the end of 2022